TY - JOUR
T1 - Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases
AU - Nozal, Vanesa
AU - Martinez, Ana
N1 - Publisher Copyright:
© 2018 Elsevier Masson SAS
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Tau-tubuline kinases (TTBK) are a family of serine/threonine and tyrosine kinases recently discovered and implicated in the phosphorylation of important substrates such as tau, tubuline or TDP-43. Its two homologs, TTBK1 and TTBK2, show different expression patterns and different involvements in physiological mechanisms of great importance such as mitosis, ciliogenesis and neurotransmission. Their phosphorylation activity has also linked them to the development of neurodegenerative diseases like Alzheimer's disease, amyotrophic lateral sclerosis or spinocerebellar ataxia type 11. There are currently only three inhibitors of these kinases described in the literature. This review intends to give an overview of the structure, expression, physiological and pathological mechanisms of both kinases as well as an extended analysis on the molecules that can inhibit them. The final analysis of all this information led us to propose TTBK1 as a new target for the treatment of neurodegenerative diseases and its selective inhibitors as potential effective drugs for the treatment of these severe unmet disorders.
AB - Tau-tubuline kinases (TTBK) are a family of serine/threonine and tyrosine kinases recently discovered and implicated in the phosphorylation of important substrates such as tau, tubuline or TDP-43. Its two homologs, TTBK1 and TTBK2, show different expression patterns and different involvements in physiological mechanisms of great importance such as mitosis, ciliogenesis and neurotransmission. Their phosphorylation activity has also linked them to the development of neurodegenerative diseases like Alzheimer's disease, amyotrophic lateral sclerosis or spinocerebellar ataxia type 11. There are currently only three inhibitors of these kinases described in the literature. This review intends to give an overview of the structure, expression, physiological and pathological mechanisms of both kinases as well as an extended analysis on the molecules that can inhibit them. The final analysis of all this information led us to propose TTBK1 as a new target for the treatment of neurodegenerative diseases and its selective inhibitors as potential effective drugs for the treatment of these severe unmet disorders.
KW - Alzheimer's disease
KW - Amyotrophic lateral sclerosis
KW - Drug candidate
KW - Neurodegenerative diseases
KW - Tau tubulin kinase 1 (TTBK1) inhibitor
KW - TDP-43
KW - TTBK2
UR - https://www.scopus.com/pages/publications/85054913093
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:000451498200004&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1016/j.ejmech.2018.10.030
DO - 10.1016/j.ejmech.2018.10.030
M3 - Short survey
C2 - 30342424
AN - SCOPUS:85054913093
SN - 0223-5234
VL - 161
SP - 39
EP - 47
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
ER -